wegovy

Danish biotech company Zealand Pharma A/S (OTC:ZLDPF) has announced encouraging topline results from a Phase 1b multiple ascending dose (MAD) trial of its weight management drug, petrelintide. The trial results were released on Thursday and comes at a time when the weightloss drug market is...

Americans love their pets: could the success of Novo Nordisk A/S (NYSE:NVO) drugs Ozempic and Wegovy and Eli Lilly And Co‘s (NYSE:LLY) Zepbound be a model for similar weight loss drugs in the pet market? What Happened: A recent Bloomberg newsletter outlined several recent developments in the...

The rise of weight loss drugs like Wegovy and Mounjaro by Novo Nordisk (NYSE:NVO) is leading to new product developments across various sectors. What Happened: Companies from food and beverage to fitness are adapting to the increased demand for these drugs, hoping to capitalize on shifting consumer...

Novo Nordisk A/S (NYSE:NVO) is facing a significant challenge in China, where local pharmaceutical companies are developing generic versions of its key diabetes and obesity drugs. What Happened: As reported by Reuters on Sunday, at least 15 Chinese drugmakers are working on generic versions of Novo...

The recently launched Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) is gaining traction among investors, primarily due to its significant holdings in pharmaceutical giants Eli Lilly and Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). These two companies are at the forefront of the burgeoning...

ReShape Lifesciences Inc. (NASDAQ:RSLS) was trading over 117% in the pre-market a day after it received the nod from the U.S. Patent And Trademark Office to issue a patent for its obesity treatment. What Happened: ReShape, which offers products and services for managing and treating obesity and...

Pharmaceutical titan, Novo Nordisk A/S (NYSE:NVO), has had a significant impact on Denmark’s employment landscape, surpassing initial projections, as revealed by a report from the Economic Councils, Denmark’s fiscal watchdog. What Happened: The Economic Councils’ report, released...

The animated comedy "South Park" is no stranger to taking on hot topics and pop culture figures in its streaming specials. After targeting cryptocurrency and artificial intelligence in recent years, the series now tackles weight-loss drugs. What Happened: "South Park" has tackled many trending...

The return of Roaring Kitty, aka Keith Gill, on social media increased interest in meme stocks and may have kickstarted a short rally to start the trading week. While there are several ETFs that provide exposure to meme stocks, an ETF that previously focused exclusively on meme stocks closed in...

Patients using Novo Nordisk’s (NYSE:NVO) (OTC:NONOF) obesity treatment, Wegovy, have reportedly maintained an average weight loss of 10% over a four-year period, as per data revealed by the company on Tuesday. This information was shared at the European Congress on Obesity in Venice, Italy....

Novo Nordisk A/S (NYSE:NVO) is witnessing a surge in the number of patients starting on its weight-loss drug, Wegovy, in the U.S. This increase comes despite supply constraints and competition from Eli Lilly & Co. (NYSE:LLY). What Happened: The Danish pharmaceutical company is now shipping more...

Denmark’s healthcare authority has decided to favor less expensive drugs for type 2 diabetes patients, impacting the prescription of costlier GLP-1 drugs such as Novo Nordisk’s (NYSE:NVO) Ozempic. This comes a day ahead of the company announcing its first-quarter earnings of 2024. What...

After a blistering performance based on the success of its weight-loss treatments Mounjaro and Zepbound, Eli Lilly & Company (NYSE:LLY) stock has been trading sideways for the last five weeks as the company struggles to keep pace with demand for the drugs. Eli Lilly shares have climbed 162%...

Costco Wholesale Corporation (NASDAQ:COST) has launched a weight management program to help its members in their weight loss journey. The program will provide access to popular weight loss medications from pharmaceutical giants Eli Lilly and Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). What...

Eli Lilly and Co. (NYSE:LLY) enjoyed meteoric success with its weight loss drugs Mounjaro and Zepbound — the latter already recording stellar sales only three months after launch in December. Recent data showed that, for the first time since launch, Zepbound filled more U.S. prescriptions in a...